The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles

C-reactive protein (CRP) has a prognostic impact in head and neck squamous cell carcinoma (HNSCC). However, the acute phase reaction involves many other proteins depending on its inducing events, including various cytokines that can function as reaction inducers. In the present study, we compared the pretreatment acute phase cytokine profile for 144 patients with potentially curative HNSCC. We investigated the systemic levels of interleukin (IL)6 family mediators (glycoprotein (gp130), IL6 receptor (R)α, IL6, IL27, IL31, oncostatin M (OSM), ciliary neurotrophic factor (CNTF)), IL1 subfamily members (IL1R antagonist (A), IL33Rα), and tumor necrosis factor (TNF)α. Patient subsets identified from this 10-mediator profile did not differ with regard to disease stage, human papilloma virus (HPV) status, CRP levels, or death cause. Increased CRP, IL6, and IL1RA levels were independent markers for HNSCC-related death in the whole patient population. Furthermore, gp130, IL6Rα, and IL31 were suggested to predict prognosis among tumor HPV-negative patients. Only IL6 predicted survival in HPV-positive patients. Finally, we did a clustering analysis of HPV-negative patients based on six acute phase mediators that showed significant or borderline association with prognosis in Kaplan–Meier analyses; three subsets could then be identified, and they differed in survival (p < 0.001). To conclude, (i) HPV-negative and HPV-positive HNSCC patients show similar variations of their systemic acute phase profiles; (ii) the prognostic impact of single mediators differs between these two patient subsets; and (iii) for HPV-negative patients, acute phase profiling identifies three patient subsets that differ significantly in survival.

Download Full-text

Arginase and C-reactive protein as potential serum-based biomarker of head and neck squamous cell carcinoma patients of north east India

Tumor Biology ◽

10.1007/s13277-014-1851-y ◽

2014 ◽

Vol 35 (7) ◽

pp. 6739-6748 ◽

Cited By ~ 7

Author(s):

Biswadeep Choudhury ◽

Shilpee Srivastava ◽

Haider H. Choudhury ◽

Alokananda Purkayastha ◽

Sumita DuttaGupta ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

C Reactive Protein ◽

North East India ◽

Reactive Protein ◽

North East

Download Full-text

The prognostic role of C‐reactive protein in patients with head and neck squamous cell carcinoma: A meta‐analysis

Cancer Medicine ◽

10.1002/cam4.3520 ◽

2020 ◽

Vol 9 (24) ◽

pp. 9541-9553

Author(s):

Yanglan Chen ◽

Rong Cong ◽

Chengjian Ji ◽

Wenhua Ruan

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Meta Analysis ◽

Neck Squamous Cell Carcinoma ◽

C Reactive Protein ◽

Prognostic Role ◽

Reactive Protein

Download Full-text

8532 Prognostic impact of comorbidity in elderly patients with head and neck squamous cell carcinoma (HNSCC)

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)71623-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 480

Author(s):

M.A. Moreno Jimenez ◽

I. Gonzalez Cebrian ◽

R. Collado Martin ◽

B. Medina Magan ◽

A.L. Ortega Granados ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Elderly Patients ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Prognostic Impact

Download Full-text

Prospective Evaluation of XRCC-1 as a Biopredictor for Survival Outcomes in Patients of Head and Neck Squamous Cell Carcinoma (HNSCC): A Meta-analysis

10.21203/rs.3.rs-698406/v1 ◽

2021 ◽

Author(s):

Fan Yang ◽

Liu-qing Zhou ◽

Yan-jun Wang

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Meta Analysis ◽

Epidemiologic Studies ◽

Neck Squamous Cell Carcinoma ◽

Survival Outcomes ◽

Prognostic Impact ◽

Meta Analyses

Abstract Background: Epidemiologic studies have demonstrated that X-ray repair cross-complementary group 1 (XRCC1) is one of the susceptibility factors in head and neck squamous cell carcinoma(HNSCC) patients. However, its clinical prognostic impact remains controversial. Thus, a meta-analysis was performed to clarify the survival value of XRCC1 in HNSCC patients.Methods: Following the Preferred Reporting Items or Systematic Reviews Meta Analyses (PRISMA) 2020 guidelines, literature searches were systematically performed by PubMed, EMBASE and Web of Science with a manual retreive to evaluate the prognostic consequence of XRCC1 in HNSCC patients. Hazard ratios (HRs) and 95% confidence intervals (CIs) were collected to estimate the correlation between XRCC1 and the survival outcomes of HNSCC patients.Results: Ten studies including 2086 HNSCC patients who satisfied the inclusion and exclusion criteria were included in this meta-analysis. The meta-analysis showed that high XRCC1 expression and Arg399Gln and Arg194Trp were significantly correlated with poorer overall survival (OS), with HRs of 1.97 (95% CI, 1.36–2.84, P<0.001), 1.30 (95% CI, 1.12–1.51, P<0.001), and 1.65 (95% CI, 1.18–2.32 P<0.05), respectively.Conclusion: XRCC1 was associated with poorer survival outcomes in HNSCC patients. Hence, XRCC1 is a potential therapeutic target for HNSCC.

Download Full-text

Prognostic Biomarkers of Salvage Chemotherapy Following Nivolumab Treatment for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Cancers ◽

10.3390/cancers12082299 ◽

2020 ◽

Vol 12 (8) ◽

pp. 2299 ◽

Cited By ~ 2

Author(s):

Takahiro Wakasaki ◽

Ryuji Yasumatsu ◽

Muneyuki Masuda ◽

Toranoshin Takeuchi ◽

Tomomi Manako ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Progression Free Survival ◽

Salvage Chemotherapy ◽

Neck Squamous Cell Carcinoma ◽

Prognostic Biomarkers ◽

Free Survival ◽

Reactive Protein

Recent studies have suggested the benefit of salvage chemotherapy (SCT) after immune checkpoint inhibitor (ICI) treatment for recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC). We retrospectively examined the outcome of SCT and the usefulness of the serum C-reactive protein level (CRP) and neutrophil-to-lymphocyte ratio (NLR) as prognostic biomarkers. Thirty-nine patients with R/M HNSCC were enrolled in this study. Twenty-five patients (64.1%) received combination chemotherapy of weekly paclitaxel and cetuximab (PC) as SCT, and 14 patients (35.9%) received tegafur-gimestat-otastat potassium (S1), an oral fluoropyrimidine. In all patients, the response rate, disease control rate, median progression-free survival (PFS), and median overall survival (OS) were 45.2%, 85.7%, 6.5 months, and 13.5 months, respectively. No chemotherapy-related deaths were observed. These PC groups had low CRP (<1.2 mg/dL) or low NLR (<7.0) values at the time of SCT induction, which was significantly associated with an improved OS (p = 0.0440, p = 0.0354). A multivariate analysis also showed that a lower CRP value was significantly associated with a better OS (p = 0.0078). We clarified the usefulness of the PC and S1 regimens as SCT. In addition, SCT with the PC regimen showed a better prognosis with a lower CRP or NLR at induction than a higher CRP or NLR. This is the first report on biomarkers of SCT in R/M HNSCC.

Download Full-text